Alkermes’ diverse portfolio of commercial products and pipeline of emerging product candidates reflects our powerful expertise in the development of innovative patient-inspired solutions. Our products are based on proprietary science and technology that provide unique treatment options for patients with debilitating diseases.
In particular, Alkermes is focused on drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record. Our aim is to develop new medicines that make significant advances for chronic CNS conditions that affect millions of patients, such as schizophrenia, major depressive disorder and pain. Click here to learn about our strong pipeline of innovative product candidates.
Within our portfolio of more than 20 approved drug products, there are currently five key commercial products that are the drivers to propel our company’s growth. Each of these products is unique in addressing patient needs in major disease areas.
Disease Areas and Approval Status
Proprietary Technologies That Span a Range of Therapeutic Areas
The Alkermes product portfolio includes more than 20 marketed products that use our proprietary technologies and span a range of major diseases.
This page is intended for healthcare professionals only.